NCT07224152招募中1 期
NBTXR3 With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung Cancer
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 40
- 试验地点
- 2
- 主要终点
- Safety and Adverse Events (AEs)
研究概览
简要总结
This is a single institution, single arm phase I/II study of NBTXR3 with radiation therapy for stage I-III advanced non-small cell lung cancer patients who are not candidates for chemotherapy or surgical resection.
详细描述
Primary Objectives:
Phase I
To evaluate the feasibility and safety of radiation therapy with NBTXR3 in LA-NSCLC with the following dose escalation:
- 45 Gy in 15 fx with NBTXR3 at 22% RP2D
- 52.5 Gy in 15 fx with NBTXR3 at 22% RP2D
- 60 Gy in 15 fx with NBTXR3 at 22% RP2D
- 60 Gy in 15 fx with NBTXR3 at 33% RP2D
Phase II
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent form (ICF) indicating that participant understands the purpose of, and procedures required for, the study and is willing to participate in the study.
- •Age ≥ 18 years.
- •ECOG Performance Status 0-2
- •Biopsy proven stage I-III NSCLC.
- •Participant deemed medically inoperable by the investigator or treating physician, or patient declines surgery.
- •No prior or concurrent systemic therapies within 4 weeks of injection. Patient may receive up to 1 line of prior systemic therapy prior to starting RT.
- •Amenable to undergo bronchoscopic (EBUS, CBCT) or CT-guided injection of NBTXR3 as per investigator or treating physician.
- •a. Up to 4 lung lesions may be injected with NBTXR3, including the primary tumor and involved lymph node(s) All injected lesions must be radiated.
- •The target lesion(s) should be measurable on cross sectional imaging (RECIST 1.1), Nodal target lesions must be ≥15mm (short axis) based on CT (slice thickness of 5mm or less) or MRI.
- •Adequate screening laboratory values
- •Hemoglobin ≥ 8.0 g/dL
- •Absolute Neutrophil Count (ANC) ≥ 1,500/mm3
- •Platelet Count ≥ 100,000/mm3
- •Creatinine ≤ 1.5 x upper limit of normal (ULN)
- •Calc. Creatinine Clearance ≥ 30 mL/min
- •Total Bilirubin ≤ 2.0 mg/dL
- •AST / ALT ≤ 3.0 x upper limit of normal (ULN) or 5.0 x ULN if known liver metastases
- •Serum albumin ≥ 3.0 g/dL Negative urine or serum pregnancy test ≤ 7 days of NBTXR3 injection in all females of child-bearing potential.
排除标准
- •Unable to undergo NBTXR3 injection via bronchoscopic or CT-guided approach
- •Unable to undergo radiation therapy for any reason
- •Female patients who are pregnant or breastfeeding.
- •Women of child-bearing potential and their male partners who are unwilling or unable to use an acceptable method of birth control to avoid pregnancy for the entire study period. Acceptable methods of contraception are those that, alone or in combination, result in a failure rate of < 1% per year when used consistently and correctly.
- •Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (e.g., compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments.
- •At screening, past medical history of:
- •Interstitial lung disease
- •Drug related pneumonitis
- •Radiation therapy to lung or other intrathoracic organs (e.g. prior breast radiation okay)
- •Has received any approved or investigational anti-neoplastic or immunotherapy agent within 4 weeks prior to NBTXR3 injection
- •Receipt of more than 1 line of systemic therapy prior to RT
- •Use of concurrent systemic therapy (chemotherapy, immunotherapy, targeted therapy) or patient participation on another therapeutic clinical trial.
- •Known contraindication to iodine-based or gadolinium-based IV contrast.
- •Active malignancy, in addition to locoregional recurrent NSCLC, with the exception of definitively treated and relapse free within 1 year from diagnosis of non-melanoma skin cancer or cervical cancer in situ; definitively treated non-metastatic prostate cancer; or patients with another primary malignancy who are definitely treated and relapse free with at least 2 years elapsed since the diagnosis of the other primary malignancy.
- •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, recent severe pulmonary infection, symptomatic congestive heart failure, unstable angina pectoris, renal failure, cardiac arrhythmia, or psychiatric illness that would limit compliance with treatment.
- •Known active, uncontrolled (high viral load) HIV or hepatitis B or hepatitis C infection
- •Cognitively impaired subjects
研究组 & 干预措施
Phase I/II: Treatment with NBTXR3 + Radiation Therapy
Experimental
干预措施: NBTXR3 (Drug)
结局指标
主要结局
Safety and Adverse Events (AEs)
时间窗: Through study completion; an average of 1 year
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
招募中
1 期
Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid MalignanciesAdvanced Malignant Solid NeoplasmMetastatic Malignant Neoplasm in the LiverMetastatic Malignant Neoplasm in the LungMetastatic Malignant Solid NeoplasmNCT05039632M.D. Anderson Cancer Center40
进行中（未招募）
1 期
NBTXR3 and Radiation Therapy for the Treatment of Inoperable Recurrent Non-small Cell Lung CancerRecurrent Lung Non-Small Cell CarcinomaStage I Lung Cancer AJCC v8Stage IA1 Lung Cancer AJCC v8Stage IA2 Lung Cancer AJCC v8Stage IA3 Lung Cancer AJCC v8Stage IB Lung Cancer AJCC v8Stage II Lung Cancer AJCC v8Stage IIA Lung Cancer AJCC v8Stage IIB Lung Cancer AJCC v8Stage III Lung Cancer AJCC v8Stage IIIA Lung Cancer AJCC v8Stage IIIB Lung Cancer AJCC v8Stage IIIC Lung Cancer AJCC v8Unresectable Lung Non-Small Cell CarcinomaNCT04505267M.D. Anderson Cancer Center34
进行中（未招募）
1 期
NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic CancerBorderline Resectable Pancreatic AdenocarcinomaLocally Advanced Pancreatic Ductal AdenocarcinomaResectable Pancreatic Ductal AdenocarcinomaStage III Pancreatic Cancer AJCC v8NCT04484909M.D. Anderson Cancer Center24
终止
2 期
NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell CancerMetastatic Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell CarcinomaNCT04862455M.D. Anderson Cancer Center14
招募中
1 期
NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal CancerCervical Esophagus AdenocarcinomaClinical Stage II Esophageal Adenocarcinoma AJCC v8Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8Clinical Stage III Esophageal Adenocarcinoma AJCC v8Gastroesophageal Junction AdenocarcinomaPathologic Stage II Esophageal Adenocarcinoma AJCC v8Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8Pathologic Stage III Esophageal Adenocarcinoma AJCC v8Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8Thoracic Esophagus AdenocarcinomaNCT04615013M.D. Anderson Cancer Center24